Accenture invests in Ryght AI to revolutionize clinical trials
Ryght AI tackles these hurdles with its AI Site Twin platform
Ryght AI tackles these hurdles with its AI Site Twin platform
This launch is part of the company's strategy to expand its nutraceutical portfolio
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
These building blocks are essential to modern therapeutics, including fast-growing GLP-1 treatments for weight loss and diabetes
The Phase-2b study is a randomized, double-blind, placebo-controlled trial that will enroll approximately 195 patients across 35 sites in the USA
The company had achieved the highest "A" rating in Climate Change
The agreement pairs Croda’s global footprint and “smart science” approach with Amino’s precision manufacturing capabilities
Expands bioprocessing footprint across Asia
Acromegaly, a rare chronic endocrine disorder caused by excess growth hormone, is seeing promising advances in treatment development
Subscribe To Our Newsletter & Stay Updated